Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5305 + apalutamide
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD5305 + apalutamide is an investigational oral combination therapy being studied for metastatic prostate cancer. AZD5305 is a next-generation, selective PARP1 inhibitor, designed to block the activity of PARP1, an enzyme involved in DNA damage repair, thereby promoting cancer cell death. Apalutamide is an oral androgen receptor inhibitor that blocks androgen signaling to inhibit prostate cancer growth. The combination aims to enhance anti-tumor efficacy by attacking two complementary pathways: DNA damage repair and androgen receptor signaling. The primary indication being studied is metastatic prostate cancer, including both castration-resistant and castration-sensitive forms. The regimen is in clinical trials for safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy[1][3][5].
- Brand names
- Erleada
- Other names
- AZD5305AZD-5305AZD 5305apalutamide
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)AR (Adrenergic receptors)
Beyond the preview
Go deeper on AZD5305 + apalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5305 + apalutamide.